Literature DB >> 2243332

Suppressive effects of morphine pellet implants on in vivo parameters of immune function.

H U Bryant1, R E Roudebush.   

Abstract

Chronic morphine treatment elicits a variety of immunosuppressive effects in mice. Most of the work describing this immuno-suppressive activity of the opioid is based on in vitro assessments of the performance of certain components of the immune system in morphine-treated animals. Relatively little has been done by way of tracking the effects of chronic morphine treatment on immunologic parameters in the intact animal. Therefore, this study used several classic in vivo determinations of immune function in mice treated chronically with morphine. Morphine pellet (75 mg) implantation led to a significant inhibition (91%) of paw swelling in a picryl chloride-induced delayed type hypersensitivity response. Uptake of iododeoxyuridine in an in vivo lymphocyte proliferation assay and splenomegaly in a graft vs. host reaction were also significantly suppressed by morphine pellet implantation (34 and 52%, respectively). Coimplantation of a naltrexone pellet (10 mg) completely reversed the suppressive responses to morphine in each assay. Naltrexone alone had no significant effect in any of the assays. The suppressive effects of morphine were less pronounced in adrenalectomized mice in the graft vs. host assay (51% vs. 9% reduction in morphine-pelleted shams relative to morphine-pelleted adrenalectomized mice). These findings indicate the pathophysiologic significance of the previously reported suppression of in vitro correlates of immune function in morphine-pelleted mice. The results further demonstrate that the immunosuppressive effects observed after morphine pellet implantation are naltrexone reversible and suggest that activation of the adrenal is one potential mechanism for this effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243332

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Pharmacologic manipulation of graft versus host induced splenomegaly.

Authors:  R E Roudebush; H U Bryant
Journal:  Agents Actions       Date:  1992-03

Review 3.  Effects of opioid tolerance and withdrawal on the immune system.

Authors:  Toby K Eisenstein; Rahil T Rahim; Pu Feng; Nita K Thingalaya; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

Review 4.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

Review 5.  Anesthetics, immune cells, and immune responses.

Authors:  Shin Kurosawa; Masato Kato
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

Review 6.  Opioids and Chronic Pain: Where Is the Balance?

Authors:  Mellar P Davis; Zankhana Mehta
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 7.  The neuroendocrine-immune axis.

Authors:  F Homo-Delarche; M Dardenne
Journal:  Springer Semin Immunopathol       Date:  1993

8.  Morphine induces splenocyte apoptosis and enhanced mRNA expression of cathepsin-B.

Authors:  P C Singhal; K Reddy; N Franki; V Sanwal; N Gibbons
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

9.  Morphine-induced enhancement in the granulocyte response to thioglycollate administration in the rat.

Authors:  Karamarie Fecho; Donald T Lysle
Journal:  Inflammation       Date:  2002-12       Impact factor: 4.092

10.  Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice.

Authors:  Megumi Aita; Margaret R Byers; Charles Chavkin; Mei Xu
Journal:  Mol Pain       Date:  2010-01-29       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.